Advertisement
Canada markets open in 8 hours 8 minutes
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7305
    +0.0007 (+0.10%)
     
  • CRUDE OIL

    82.94
    +0.13 (+0.16%)
     
  • Bitcoin CAD

    87,814.89
    -3,694.49 (-4.04%)
     
  • CMC Crypto 200

    1,388.73
    -35.37 (-2.48%)
     
  • GOLD FUTURES

    2,328.80
    -9.60 (-0.41%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,440.75
    -223.75 (-1.27%)
     
  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    37,668.29
    -791.79 (-2.06%)
     
  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     

Novavax's New CEO Leads Vaccine Trial Success, and Big Layoffs Too

Novavax's New CEO Leads Vaccine Trial Success, and Big Layoffs Too

Novavax (NASDAQ: NVAX) investors have been on edge ever since the company fell behind in the coronavirus vaccine race. To make matters worse, earlier this year, Novavax even questioned its ability to continue operations. Jacobs revealed details about his strategy to cut costs, manage cash flow, and match Novavax's size to the demand for its only product: the coronavirus vaccine.